ReviewCells2022
Metabolic Profiling of CHO Cells during the Production of Biotherapeutics.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Improving recombinant protein productivity in CHO cells via multi-omics data integration.Bioresources and bioprocessing · 2026Review
- Osmolality-Independent Impact of Sodium on Glycosylation of an Fc-Fusion Protein and the Hexosamine Biosynthesis Pathway in a Chinese Hamster Ovary Cell Line.Biotechnology journal · 2026Article
- Challenges and solutions for upstream processing of complex biologics.Antibody therapeutics · 2026Review
- Whole-genome DNA methylation analysis of Chinese hamster ovary cells undergoing media adaptation.Frontiers in bioengineering and biotechnology · 2026Article
- Integration of Bayesian optimization and solution thermodynamics to optimize media design for mammalian biomanufacturing.iScience · 2025Article
- Flux Sampling Suggests Metabolic Signatures of High Antibody-Producing CHO Cells.Biotechnology and bioengineering · 2025Article
- Novel Data-Driven Mechanistic Modeling of Untargeted Metabolome Data Reveals Feed Component Effects in CHO Cell Bioprocess Using Column Generation-Based EFMs.Biotechnology journal · 2025Article
- QuantitativeAnalytical and bioanalytical chemistry · 2025Article
- Evaluating Apoptotic Gene Efficiency for CHO Culture Performance Using Targeted Integration.ACS synthetic biology · 2025Article
- Monitoring of Nutrients, Metabolites, IgG Titer, and Cell Densities in 10 L Bioreactors Using Raman Spectroscopy and PLS Regression Models.Pharmaceutics · 2025Article
- Time-Resolved Hierarchical Modeling Highlights Metabolites Influencing Productivity and Cell Death in Chinese Hamster Ovary Cells.Biotechnology journal · 2025Article
- Accelerating biopharmaceutical cell line selection with label-free multimodal nonlinear optical microscopy and machine learning.Communications biology · 2025Article
- Characterization and design of dipeptide media formulation for scalable therapeutic production.Applied microbiology and biotechnology · 2025Review
- Identification of cellular signatures associated with chinese hamster ovary cell adaptation for secretion of antibodies.Computational and structural biotechnology journal · 2025Article
- mAb production kinetics in CHO batch culture: exploring extracellular and intracellular dynamics.Frontiers in bioengineering and biotechnology · 2025Article
- Single-Use, Metabolite Absorbing, Resonant Transducer (SMART) Culture Vessels for Label-Free, Continuous Cell Culture Progression Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Advancements in CHO metabolomics: techniques, current state and evolving methodologies.Frontiers in bioengineering and biotechnology · 2024Review
- Article
- Employing active learning in the optimization of culture medium for mammalian cells.NPJ systems biology and applications · 2023Article
- Long term culturing of CHO cells: phenotypic drift and quality attributes of the expressed monoclonal antibody.Biotechnology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As indicated by an ever-increasing number of FDA approvals, biotherapeutics constitute powerful tools for the treatment of various diseases, with monoclonal antibodies (mAbs) accounting for more than 50% of newly approved drugs between 2014 and 2018 (Walsh, 2018). The pharmaceutical industry has made great progress in developing reliable and efficient bioproduction processes to meet the demand for recombinant mAbs. Mammalian cell lines are preferred for the production of functional, complex recombinant proteins including mAbs, with Chinese hamster ovary (CHO) cells being used in most instances. Despite significant advances in cell growth control for biologics manufacturing, cellular responses to environmental changes need to be understood in order to further improve productivity. Metabolomics offers a promising approach for developing suitable strategies to unlock the full potential of cellular production. This review summarizes key findings on catabolism and anabolism for each phase of cell growth (exponential growth, the stationary phase and decline) with a focus on the principal metabolic pathways (glycolysis, the pentose phosphate pathway and the tricarboxylic acid cycle) and the families of biomolecules that impact these circuities (nucleotides, amino acids, lipids and energy-rich metabolites).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.